Lucid Diagnostics Inc (NASDAQ: LUCD)’s stock price has decreased by -2.94 compared to its previous closing price of 1.19. However, the company has seen a -8.33% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-18 that Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK, June 18, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics’ EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, primary care, and concierge medicine programs.
Is It Worth Investing in Lucid Diagnostics Inc (NASDAQ: LUCD) Right Now?
Additionally, the 36-month beta value for LUCD is 1.27. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LUCD is 40.34M and currently, short sellers hold a 4.11% ratio of that float. The average trading volume of LUCD on June 27, 2025 was 1.20M shares.
LUCD’s Market Performance
LUCD stock saw a decrease of -8.33% in the past week, with a monthly decline of -24.01% and a quarterly a decrease of -27.36%. The volatility ratio for the week is 6.05%, and the volatility levels for the last 30 days are 6.75% for Lucid Diagnostics Inc (LUCD). The simple moving average for the last 20 days is -7.56% for LUCD stock, with a simple moving average of 5.22% for the last 200 days.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at -9.06% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.83% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUCD starting from Matheis Dennis, who purchase 187,098 shares at the price of $1.29 back on May 20 ’25. After this action, Matheis Dennis now owns 187,098 shares of Lucid Diagnostics Inc, valued at $242,292 using the latest closing price.
Matheis Dennis, the Director of Lucid Diagnostics Inc, purchase 129,684 shares at $1.32 during a trade that took place back on May 21 ’25, which means that Matheis Dennis is holding 316,782 shares at $171,520 based on the most recent closing price.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -15.06 for the present operating margin
- -0.87 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -43.37. The total capital return value is set at 3.32. Equity return is now at value -1897.35, with -190.69 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 1.18 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at -6.56. The interest coverage ratio of the stock is 1393.53.
Currently, EBITDA for the company is -44.34 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 12.22. The receivables turnover for the company is 13.63for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.75.
Conclusion
In conclusion, Lucid Diagnostics Inc (LUCD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
